Appendix cancer differential diagnosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 30: Line 30:
! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings
|-
|-
| colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
Line 108: Line 107:


| style="background: #F5F5F5; padding: 5px;" |[[Biopsy]]
| style="background: #F5F5F5; padding: 5px;" |[[Biopsy]]
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid tumor<sup>2</sup>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid tumor<sup>2</sup>
Line 141: Line 139:
'''Microscopic pathology:'''
'''Microscopic pathology:'''
|[[Biopsy]]
|[[Biopsy]]
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| colspan="2" |[[Ovarian cancer differential diagnosis|Ovarian cancer]]
| colspan="2" |[[Ovarian cancer differential diagnosis|Ovarian cancer]]
| style="background: #F5F5F5; padding: 5px;" |+/-
| style="background: #F5F5F5; padding: 5px;" | +/-
| style="background: #F5F5F5; padding: 5px;" |+/-
| style="background: #F5F5F5; padding: 5px;" | +/-
| style="background: #F5F5F5; padding: 5px;" |-
| style="background: #F5F5F5; padding: 5px;" | -
|<nowiki>+/-</nowiki>
|<nowiki>+/-</nowiki>
|
|
Line 153: Line 150:
* Dyspnea  
* Dyspnea  
* GI disturbance  
* GI disturbance  
| style="background: #F5F5F5; padding: 5px;" |+
| style="background: #F5F5F5; padding: 5px;" | +
| style="background: #F5F5F5; padding: 5px;" |+/-
| style="background: #F5F5F5; padding: 5px;" | +/-
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Ascites]]  
* [[Ascites]]  
Line 160: Line 157:
* Fever  
* Fever  
* Pleural effusion  
* Pleural effusion  
| style="background: #F5F5F5; padding: 5px;" |-
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |-
| style="background: #F5F5F5; padding: 5px;" | -
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* '''Depends on the underlying etiology'''
* '''Depends on the underlying etiology'''
Line 186: Line 183:
* Adnexal mass
* Adnexal mass
* Adenexal Cyst (simple or complex)
* Adenexal Cyst (simple or complex)
* ovarian mass are generally hyperintense on T1 and hypo or isointense on T2 imaging
* Except for [[Thecoma]], ovarian masses are generally hyperintense on T1 and hypo or isointense on T2 imaging
* Fluid accumulation
* Fluid accumulation
* Endometrial thickening
* Endometrial thickening
Line 201: Line 198:
* calcification
* calcification


| style="background: #F5F5F5; padding: 5px;" |N/A
| style="background: #F5F5F5; padding: 5px;" |Depends on the tumor type. You may find the details [[Ovarian cancer differential diagnosis|here]].
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
|-
|-
| colspan="2" |
| colspan="2" |
|
|
|
|
|
Line 227: Line 223:
|-
|-
| colspan="2" |
| colspan="2" |
|
|
|
|
|
Line 268: Line 263:
* Typically does not invade visceral organs or spread by [[lymphatic]] or hematogenous routes unlike mucinous carcinomatosis
* Typically does not invade visceral organs or spread by [[lymphatic]] or hematogenous routes unlike mucinous carcinomatosis
|
|
Characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. MRI has better sensitivity in detecting ascites fluid and mucocele.
|
|
* The echoes within pseudomyxoma peritonei are not mobile.
* The echoes within pseudomyxoma peritonei are not mobile.
* Echogenic septations within the gelatinous ascites.
* Echogenic septations within the gelatinous ascites.
* Scalloping of the [[hepatic]] and splenic margins
* Scalloping of the [[hepatic]] and splenic margins
|
|18F-FDG [[PET scan]]
|
|
* Depending on [[WHO]]<nowiki/>classification, whether it's low or high grade with cellular atypia or acellular mucin. ( DPAM, PMCA)
* Depending on [[WHO]]<nowiki/>classification, whether it's low or high grade with cellular atypia or acellular mucin. ( DPAM, PMCA)
Line 285: Line 282:
|
|
* Diagnostic laparascopy/laparatomy
* Diagnostic laparascopy/laparatomy
|
|-
|-
| colspan="2" |Carcinoid syndrome
| colspan="2" |Carcinoid syndrome
Line 329: Line 325:
* [[Endoscopic]] [[ultrasonography]] (EUS)  
* [[Endoscopic]] [[ultrasonography]] (EUS)  


|
|
|
|
|
Line 373: Line 368:
|[[Tc-99m]] labeled anti-[[CD15]] [[antibodies]]  
|[[Tc-99m]] labeled anti-[[CD15]] [[antibodies]]  
|Evidences of [[inflammation]]
|Evidences of [[inflammation]]
|CT scan
|A combination of Imaging (ultrasonography or CT scan, while CT scan is more sensitive), physical exam and history
|[[Appendicitis diagnostic scoring|Alvarado Score]]
[[Appendicitis diagnostic scoring|Alvarado Score]]
|-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|}
|}



Revision as of 22:46, 8 February 2019

Appendix cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Epidemiology and Demographics

Differentiating Appendix cancer from other Diseases

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

MRI

CT scan

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Appendix cancer differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Appendix cancer differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Appendix cancer differential diagnosis

CDC on Appendix cancer differential diagnosis

Appendix cancer differential diagnosis in the news

Blogs on Appendix cancer differential diagnosis

Directions to Hospitals Treating Appendix cancer

Risk calculators and risk factors for Appendix cancer differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]

Overview

appendix cancer must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

OR

appendix cancer must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].

Differentiating appendix cancer from other Diseases

appendix cancer must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].

OR

appendix cancer must be differentiated from [differential dx1], [differential dx2], and [differential dx3].

OR

As appendix cancer manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].

Differentiating appendix cancer from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]

On the basis [symptom 1], [symptom 2], and [symptom 3], appendix cancer must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].

Diseases Clinical manifestations Para-clinical findings Gold standard
Symptoms Physical examination
Lab Findings Imaging Histopathology
Abdominal pain Change in girdle size Change in bowel habits Other symptoms Abdominal mass abdominal tenderness Other physical examination findings Urinary 5-hydroxyindoleacetic acid (5-HIAA) Serum Chromogranin A (CgA) Other lab findings CT scan MRI Utrasounography Other imaging modalities
Diarrhea Constipation
Appendix cancer Adenocarcinoma1 +/- -/+ - +
  • Generally asymptomatic
  • Appendicitis symptoms
  • Nausea & vomiting,decreased appetite Anorexia
  • No gas or stool pass (intestinal obstruction)
  • Bone pain (bone metastasis)
  • Bloating (ascites)
- - - -
  • CEA
  • CA 19-9
  • Soft tissue thickening
  • Wall irregularity
  • Presence of pseudomyxoma peritonei
  • Calcification
  • Internal septations
  • Periappendiceal fat stranding and intraperitoneal free fluid which is a nonspecific finding
  • Cystic lesion
  • Diffusion weighted MRI has been shown to be the modality of choice for peritoneal carcinomatosis
  • Increased fluid signal on T2 weighted sequence
  • Soft tissue mass in the appendix
  • Invasion to other structures
  • Dilated appendix
  • Periappendiceal fluid collection
  • Distinct appendix wall layers
Positron emission tomography (PET) Gross pathology:
  • Gray/yellowi color
  • Cystic structures with angiolymphatic invasion

Microscopic pathology:

Biopsy
Carcinoid tumor2 +/- - + -
  • Generally asymptomatic
  • Flushing
  • Palpitation
  • Dyspnea
- -
  • Tricuspid regurgitation
  • murmur
  • Wheezing
+ +
  • Ki67: a reliable marker of cell proliferation
Gross pathology:
  • Gray/yellowi color
  • Cystic structures with angiolymphatic invasion

Microscopic pathology:

Biopsy
Ovarian cancer +/- +/- - +/-
  • Pelvic/abdominal pain or pressure
  • Vaginal bleeding/discharge
  • Dyspnea
  • GI disturbance
+ +/-
  • Ascites
  • Shifting dullness
  • Fever
  • Pleural effusion
- -
  • Depends on the underlying etiology
  • Iron
  • HCG
  • LDH
  • Calcium
  • Estrogen
  • progestron
  • Testosterone
  • AFP
  • CA 125
  • Ki 67
  • Adnexal mass
  • Adenexal Cyst (simple or complex)
  • Fluid accumulation
  • Endometrial thickening
  • calcification
  • Pleural effusion
  • Peritoneal involvement
  • Lymphandenopathy
  • Adnexal mass
  • Adenexal Cyst (simple or complex)
  • Except for Thecoma, ovarian masses are generally hyperintense on T1 and hypo or isointense on T2 imaging
  • Fluid accumulation
  • Endometrial thickening
  • calcification
  • Pleural effusion
  • Peritoneal involvement
  • Lymphandenopathy
  • Adnexal mass
  • Adenexal Cyst (simple or complex)
  • Fluid accumulation
  • Increased Doppler flow
  • Endometrial thickening
  • calcification
N/A Depends on the tumor type. You may find the details here.
  • Biopsy
Pseudomyxoma peritonei + + -/+ -/+ Bloating - + Ascites

Shifting dullness

- -
  • Non specific
  • Depends on the etiology of the disease
  • Low-attenuation
  • Scalloping of the visceral surfaces differentiates pseudomyxoma from other causes of peritnoitis.
  • Typically does not invade visceral organs or spread by lymphatic or hematogenous routes unlike mucinous carcinomatosis

Characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. MRI has better sensitivity in detecting ascites fluid and mucocele.

  • The echoes within pseudomyxoma peritonei are not mobile.
  • Echogenic septations within the gelatinous ascites.
  • Scalloping of the hepatic and splenic margins
18F-FDG PET scan
  • Depending on WHOclassification, whether it's low or high grade with cellular atypia or acellular mucin. ( DPAM, PMCA)
  • Gelatinous ascites in peritoneum and visceralorgans,usually underneath the right hemidiaphragm, liver.
  • Omental cake
    • Immunohistochemisty
  • Diagnostic laparascopy/laparatomy
Carcinoid syndrome -/+ - + - Flushing

Palpitation

Dyspnea

- -
  • Tricuspid regurgitation
  • murmur
  • Wheezing
+ + Depends on the primary tumor location and type Depends on the primary tumor location and type Depends on the primary tumor location and type
Appendicitis 3 LLQ / RRQ - -/+
  • Intermittent
  • Secretory type
+ Nausea & vomiting,decreased appetite

Anorexia

+/- + - - Appendiceal wall thickening /perforation

peri-appendiceal inflammation, fluid accumulation,fat stranding

Increased fluid signal on T2 weighted sequence Evidences of inflammation
  • Dilated appendix
  • Periappendiceal fluid collection
  • Distinct appendix wall layers
Tc-99m labeled anti-CD15 antibodies Evidences of inflammation A combination of Imaging (ultrasonography or CT scan, while CT scan is more sensitive), physical exam and history

Alvarado Score

1 Adenocarcinomas usually present with appendicitis, barely they might present with Pseudomyxoma peritonei; meanwhile Pseudomyxoma peritonei is more prevalent in perforated mucocele, goblet cell tumor or high stages of adenocarcinoma.

2 Generally appendix carcinoids are asymptomatic, they were only become symptomatic if they metastasize to the liver, or in rare cases make an obstruction and present with appendicitis which is quit uncommon in appendiceal carcinoids compared to appendiceal adenocarcinoma. Any patient with carcinoid syndrome should be evaluated for appendix carcinoids.

3 Every patient with appendicitis should be evaluated for appendix cancer, 0.5 in 100 appendicitis cases are because of appendix cancer.

References

Template:WH Template:WS